PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Polyglactin 910”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1979

Arterial regeneration following polyglactin 910 suture mesh grafting.

A suture mesh of polyglactin 910 [Vicryl (polyglactin 910) suture mesh] was placed as a patch graft into the thoracic aorta of 23 growing pigs. In three other pigs the mesh was grafted in the form of a tube to replace a short aortic defect. The biological processes taking place in the grafted area were studied by morphological methods. The following observations were made: (1) Hemostasis readily occurred by fibrin, platelet, and erythrocyte embedding of the mesh. (2) Early outgrowth of smooth muscle cells around the mesh took place from the normal aortic media and from a newly formed subintimal smooth muscle layer. (3) The newly formed arterial tissue was completely endothelialized within 20 days. (4) The polyglactin mesh had disappeared almost completely at 40 days, but the new wall seemed to retain sufficient strength throughout the observation time. (5) Only irregular deposition of elastic fibrils occurred, but in other respects the new tissue structurally resembled normal arterial tissue.

Animals↗
PubMed1975

The evaluation of 7-0 Polyglactin 910 suture in cataract surgery.

The new synthetic absorbable suture, Polyglactin 910, represents a significant step toward absorbable suture perfection. In 218 cataract surgical procedures, the performance of Polyglactin 910 was compared to that of Chromic Catgut and Chromic Collagen. The results obtained in this series of cases is the basis for this article. When compared to Chromic Catgut and Chromic Collagen, Polyglactin 910 consistently provided greater tensile strength, improved handling, significantly decreased tissue reaction, more batch-to-batch uniformity, superior wound tensile strength retention, and a predictable absorption rate that is virtually completed in 35 days. Both nonprotein and nonantigenic, Polyglactin 910 evoked less tissue reaction and proved more versatile and reliable than either of the other sutures.

Absorption↗
PubMed1976

An evaluation of 8-0 Polyglactin 910 synthetic absorbable suture in cataract surgery.

This study describes the operative and postoperative performance of 8-0 Polyglactin 910 in cataract surgery. The evaluation represents a clinical comparison of 7-0 Polyglactin 910 to the same suture in 8-0 size in 155 cataract surgical procedures. In 45 cases, 8-0 Polyglactin 910 was the sole wound closure material used. 8-0 Polyglactin 910 provided high tensile strength, good knot security, batch-to-batch uniformity, ease of handling, minimal reaction, and a predictable absorption rate that was virtually completed in 33 days. When compared to 7-0 Polyglactin 910, 8-0 produced less tissue drag, fibrillation, and reaction. Early in our series, three cases of wound dehiscence occurred. One was caused by trauma and the other two by 8-0 Polyglactin 910 cutting through tissue. This study's conclusion stresses avoiding the tendency of tying the knot too tightly to prevent suture pull-out.

Absorption↗
PubMed1977

Experiences with polyglactin 910 (Vicryl) in general surgery.

The physical properties of polyglactin 910 (Vicryl) have been studied experimentally and clinically and compared with other synthetic and natural suture materials. Polyglactin 910 has a relatively high fluid absorption capacity but a low capillary capacity. The tensile strength is high and well comparable with, or superior, to other synthetic non-absorbable suture materials commonly used. The elongation at break is moderate. No unfavourable wound reaction to the suture material has been registered. The material has not increased the expected frequency of wound infections. The follow up of laparotomized patients 12-18 months after the operation showed a very low frequency of wound hernia. Neither was any recurrence noticed after repair of inguinal hernia. No clinical signs of leakage in the anastomoses of the gastrointestinal region was registrated. It is concluded that polyglactin 910 in a wide extent seems to be able to replace catgut and also non-absorbable suture materials when normal wound healing is to be expected.

Absorption↗
PubMed1977

Polyglactin 910 suture in urinary tract.

Cystotomies in guinea pigs and ureteral anastomoses in dogs were sutured with polyglactin 910. Silk and chromic catgut were used as control sutures in the bladders and chromic catgut in the ureters. Three months postoperatively in bladders sutured with polyglactin 910 small epithelial cysts were noted, which increased in size with time. In ureters sutured with polyglactin 910 cystic diverticula were observed eight months postoperatively. Because of the difference of tissue reaction to polyglactin 910 compared with catgut, further long-term studies are urged in different species of animals, prior to the clinical use of polyglactin 910 in the urinary tract.

Animals↗
PubMed1975

The use of Polyglactin 910 in muscle surgery.

This study represents the clinical evaluation of a newly developed snythetic absorbable suture, Polyglactin 910, in 5-0 and 6-0 sizes as used in muscle surgery. In 240 cases, Polyglactin 910 has spoken very well for itself. It possesses extremely high tensile strength and wound tensile strength retention, excellent handling characteristics and a predictable absorption rate, while the amount of tissue reaction it produces is consistently less than that of comparably sized sutures of Chromic Catgut. Polyglactin 910 is both versatile and reliable, and reflects important progress toward the development of "the perfect" absorbable suture. This article details Polyglactin 910's shortcomings as well as its strong points, and provides a recommended handling technique for its use.

Absorption↗
PubMed1989

[Anastomoses of the small intestine in a septic environment protected by polyglactin 910-collagen mesh. Experimental study in rats].

An experimental study was carried out in rats to evaluate the outcome of small bowel anastomoses in the presence of peritonitis with and without protection by a polyglactin 910 mesh. One hundred and thirty rats were operated. 1) Thirty small bowel anastomoses were performed in a sterile environment to evaluate the morbidity and mortality due to the surgical procedure itself. All these animals had an uneventful course. 2) Forty anastomoses were performed in a septic environment without protection. Twelve rats died immediately after the procedure. Six rats developed an anastomotic fistula and 22 had an uneventful course. 3) Sixty anastomoses were performed in a septic environment and protected by a polyglactin 910 mesh. Seventeen rats died immediately after the procedure. There were no anastomotic disruptions. Seventeen rats had an uneventful course, and 28 (65%) developed stenosis of the anastomosis. Protection of small bowel anastomoses by a polyglactin 910 mesh appears to effectively prevent disruptions (no anastomotic fistulae or locoregional infections were recorded). However, the mesh is responsible for an intense inflammatory reaction, that often results in intestinal obstruction.

Anastomosis, Surgical↗
PubMed1976

Polyglactin 910 suture absorption and the role of cellular enzymes.

Enzyme histochemical procedures for both hydrolase and oxidoreductase enzyme activity were applied to cryostat sections of polyglactin 910 suture implant sites. Sutures were implanted either solely in tissue or in a combination of in vitro incubation followed by implantation in vivo for total time periods of seven to 56 days. Suture absorption rates were also measured. It is concluded from the results that neither cellular nor enzyme activity is necessary for the degradation and absorption of polyglactin 910 sutures. This conclusion is based on similar absorption rates for sutures implanted solely in vivo and sutures treated in vitro and then implanted in tissue to give equivalent time spans. There were strong indications, however, that the products of suture hydrolysis are probably metabolized through the oxidative enzyme systems of cells adjacent to the suture. This mechanism of polyglactin 910 suture absorption is quite different from that observed and reported for catgut absorbable sutures.

Absorption↗
PubMed1991

Treatment of periodontal defects with an absorbable membrane (polyglactin 910) with and without osseous grafting: case reports.

The purpose of these reports is to illustrate the possible use of polyglactin 910 as an absorbable membrane for periodontal healing. Eleven surgical sites in 10 patients are reported. Vicryl mesh was used on all sites, and osseous allograft material was used in 8 of these sites. Radiographic evaluation and sounding with anesthesia indicate improvement in the treated areas. Few adverse effects were seen at the treated sites. Therefore, polyglactin offers promise as a material for use in periodontal therapy, especially in deep infrabony pockets. Further controlled studies comparing polyglactin 910 and other resorbable materials as barrier membranes are needed to establish their safety and efficacy.

Adult↗
PubMed1978

Cataract wound closure with polyglactin 910 following insertion of a 4-loop Binkhorst lens: preliminary report.

In this preliminary report our results with 8-0 braided polyglactin 910 suture for cataract wound closure after insertion of a 4-loop Binkhorst lens were encouraging. However, more experience is required before valid conclusions can be reached regarding its safety. Early experience indicates that the surgeon should approach the use of 9-0 monofilament polyglactin 910 suture for cataract wound closure following insertion of an intraocular lens with extreme caution.

Cataract Extraction↗
PubMed1992

Adhesion formation to incisional abdominal wound in response to polyamide "6" and polyglactin "910" sutures.

Frequency of adhesion formation to laparotomy wound scar in response to absorbable and non-absorbable synthetic sutures and closure technique was studied. Polyglactin "910" (synthetic absorbable) and polyamide "6" (synthetic non-absorbable) sutures were compared employing both mass and layered closure technique. Layered closure with polyglactin "910" closure developed maximum number of adhesions to laparotomy scar.

Abdomen↗
PubMed1979

A comparative evaluation of 9-0 monofilament and 9-0 braid polyglactin 910 in cataract surgery (intracapsular, extracapsular, and phacoemulsification).

This study describes the operative and postoperative performance of 9-0 monofilament and 9-0 braid Polyglactin 910 synthetic absorbable sutures in cataract surgery. The evaluation represents a clinical comparison of the sutures in 150 cataract surgical procedures. In a comparative evaluation each suture provided specific performance advantages: (table: see text). To date, the 9-0 monofilament and 9-0 braid Polyglactin 910 sutures are the smallest useful absorbable sutures developed for cataract surgery. While these sutures seem safe for use with phacoemulsification as sole wound closure materials, we recommend the use of nylon stints for intracapsular and extracapsular procedures until further experience is gained.

Cataract Extraction↗
PubMed1989

A comparative study of polydioxanone (PDS) and polyglactin 910 (Vicryl) in colonic anastomoses in rats.

The use of polyglactin 910 (Vicryl) in colonic anastomoses is theoretically undesirable because its short dissolution time and multifilament structure may lead to local sepsis and anastomotic leakage. We have compared Vicryl with a newly introduced monofilament absorbable suture which has a longer dissolution time than Vicryl. In a study of 98 rat colonic anastomoses no difference was found in complication rates or cellular reaction to the suture material between Vicryl and polydioxanone (PDS). The use of monofilament suture with longer dissolution time does not necessarily imply added security for colonic anastomoses.

Anastomosis, Surgical↗
PubMed1979

Coated Vicryl (polyglactin 910) suture in extraocular muscle surgery.

A newly available coated Vicryl (Polyglactin 910) suture was evaluated in laboratory and clinical trials for use in extraocular muscle surgery. The suture retains the increased strength and low antigenicity of uncoated Vicryl suture, while providing easier passage through tissue and improved tying characteristics. The improved handling properties result from the coating which produces a smoother suture surface.

Adolescent↗
PubMedDate not supplied

[Trial of a synthetic absorbable suture, Polyglactin 910, in 100 urologic patients].

The authors studied the clinical tolerance of Polyglactine 910 (Vicryl) in 100 patients operated upon for urological disorders. The operations were mostly for ureterovesical reimplantations to treat reflux, pyelocaliceal kidney stones and ureteral calculi, and prostatic adenomectomy. The suture appears to be solid, and the knots do not loosen. It slides badly however and is not easy to manipulate. When used to close cavity walls this solid suture did not cause a higher percentage of abscess than catgut, when used to suture the urinary excretory tract the authors observed, in one case only, multiple calcification around the ureterovesical suture points and those used to close the bladder. The suture is not suitable for vaginal repair operations during the surgical treatment of incontinence. The authors conclude by defining the properties of a suture they would like to see become available: one which has the same solidity, is easier to manipulate, slides more easily, and, above all, has a different texture: a monofilament rather than a braided suture.

Catgut↗
PubMed1989

Repair of spinal dural defects with vicryl (polyglactin 910) mesh.

This study examined and compared the effectiveness of woven vicryl (polyglactin 910) mesh and lyophilized cadaver dura (Lyodura) for the repair of spinal dural defects. A woven vicryl mesh was used to repair spinal dural defects in 16 mongrel dogs. As an internal control, all animals had a separate dural incision that was closed with 9-0 vicryl suture. Animals were killed, and results were evaluated at 4, 8, 12, and 24 weeks. The repair of dural defects was achieved in all animals, and there were no cases of pseudo-meningocele formation, cerebrospinal fluid leakage, or postoperative infection. The vicryl mesh served as a latticework for formation of a neodural membrane. Inflammatory or reactive response to vicryl mesh was minimal, and no adhesion to underlying neural structures was noted. The neodural membrane formed in the animals in which lyophilized dura was employed was usually thicker than those in which vicryl mesh was used and was associated with thick arachnoid-neural adhesions in two of eight animals. We believe vicryl mesh is a suitable dural substitute and offers promise for use in clinical situations.

Animals↗
PubMed1975

A biologic comparison of polyglactin 910 and polyglycolic acid synthetic absorbable sutures.

Two synthetic absorbable sutures were implanted in rats for a comparative evaluation of breaking strength, tissue reaction and absorption. Polyglactin 910 suture was stronger than polyglycolic acid suture in both sizes tested and at all time periods from zero to 35 days. Both suture types elicited minimal tissure response. Based upon histologic examination, virtually all remnants of the polyglactin 910 were absorbed by 90 days, while considerable quantities of polyglycolic acid persisted at 120 days. The difference in absorption rates was a highly significant feature of the comparative biologic profiles of the two suture materials.

Animals↗